Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a ...

Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation.

Some analysts are wondering whether the market can absorb the artificial intelligence giant’s planned stock offering — along ...

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental ...

An analyst sees massive upside after the Novo Nordisk deal.

Critterz, a feature-length cartoon intended to showcase how OpenAI’s video-generation capabilities could revolutionize filmmaking, has missed a planned Cannes Film Festival debut after the artificial ...

BENGALURU, May 22 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish ...

The world’s most popular weight-loss and diabetes drugs are linked to a powerful new possible benefit: better outcomes for cancer patients. A suite of four new studies suggests that people taking ...

Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicines regulator said on Friday. The European Medicines Agency said it ...

Uncovering nature’s secrets is no easy task. The daily life of a scientist is often grueling, frustrating, and—perhaps surprisingly—boring as they repeat experiments over and over. Here’s where AI ...

Add Yahoo as a preferred source to see more of our stories on Google. Sam Altman opened up about his experience using semaglutide, a GLP-1 drug sold under the names Wegovy and Ozempic, and the ...

I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer ...